Dexcom Board expands to 12; appointed Albert F.
Filed with the SEC on · Summarized by InvestorsBot
Dexcom Board expands to 12; appointed Albert F. “Rick” Osterloh IV as director effective Feb 26, 2026. Term expires at the 2026 annual meeting. He joins the Compensation and Technology Committees. 🧑💼🔧 $DXCM #CorporateGovernance #MedTech
Board determined Osterloh is independent, reports no related‑party transactions, and he signed Dexcom’s standard director indemnity agreement. No selection arrangements disclosed. 🛡️ $DXCM #Governance #Board
Comp plan: initial RSUs valued $500,000 vesting annually over 3 yrs; pro‑rata annual RSUs $101,027 (from $325,000 base) for service to 2026 meeting. Annual award vests at next annual meeting or 1 yr; full acceleration on change‑in‑control. 💸 #Compensation #DXCM